Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 30, 2023

SELL
$191.51 - $216.16 $10,533 - $11,888
-55 Reduced 0.43%
12,633 $2.68 Million
Q2 2023

Aug 04, 2023

BUY
$187.64 - $206.25 $184,074 - $202,331
981 Added 8.38%
12,688 $2.44 Million
Q4 2022

Jan 26, 2023

SELL
$117.37 - $139.17 $36,032 - $42,725
-307 Reduced 2.56%
11,707 $0
Q3 2022

Oct 19, 2022

BUY
$135.27 - $180.11 $169,222 - $225,317
1,251 Added 11.62%
12,014 $1.64 Million
Q2 2022

Jul 13, 2022

SELL
$108.81 - $179.33 $35,472 - $58,461
-326 Reduced 2.94%
10,763 $1.9 Million
Q1 2022

Apr 19, 2022

SELL
$119.61 - $157.85 $8,851 - $11,680
-74 Reduced 0.66%
11,089 $1.6 Million
Q4 2021

Jan 20, 2022

BUY
$142.57 - $190.86 $515,390 - $689,958
3,615 Added 47.89%
11,163 $1.73 Million
Q3 2021

Oct 15, 2021

SELL
$142.45 - $169.82 $6,980 - $8,321
-49 Reduced 0.64%
7,548 $1.28 Million
Q2 2021

Jul 19, 2021

SELL
$135.08 - $161.1 $6,754 - $8,055
-50 Reduced 0.65%
7,597 $1.2 Million
Q1 2021

May 07, 2021

BUY
$137.51 - $190.8 $24,614 - $34,153
179 Added 2.4%
7,647 $1.06 Million
Q4 2020

Feb 02, 2021

BUY
$164.63 - $211.93 $1.23 Million - $1.58 Million
7,468 New
7,468 $1.31 Million

Others Institutions Holding SGEN

About Seagen Inc.


  • Ticker SGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,664,992
  • Description
  • Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...
More about SGEN
Track This Portfolio

Track Sumitomo Mitsui Ds Asset Management Company, LTD Portfolio

Follow Sumitomo Mitsui Ds Asset Management Company, LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sumitomo Mitsui Ds Asset Management Company, LTD, based on Form 13F filings with the SEC.

News

Stay updated on Sumitomo Mitsui Ds Asset Management Company, LTD with notifications on news.